- Home
- EDF vs ORMP Comparison
EDF vs ORMP Comparison
Compare EDF & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | ORMP |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 165.3M |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EDF | ORMP |
|---|---|---|
| Price | $5.28 | $4.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 161.3K | ★ 516.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.39 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $4.72 | $1.98 |
| 52 Week High | $5.67 | $5.19 |
Technical Indicators
Market Signals| Indicator | EDF | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 42.74 |
| Support Level | $4.81 | $3.69 |
| Resistance Level | $5.35 | $4.22 |
| Average True Range (ATR) | 0.09 | 0.33 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 5.41 | 3.52 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.